FFA
ACTU

Farther Finance Advisors’s Actuate Therapeutics ACTU Stock Holding History

Farther Finance Advisors’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70 Buy
46
+39
+557% +$90 ﹤0.01% 5824
2026
Q1 		$17 Buy
+7
New +$29 ﹤0.01% 5664

Other funds holding ACTU

GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
AA
ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
GRWP
Green Ridge Wealth Planning Montville, New Jersey $238M AUM
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Farther Finance Advisors's ACTU Position: Q2 2026 in Review

Farther Finance Advisors increased its Actuate Therapeutics (ACTU) stake by 557% in Q2 2026, buying an estimated $90 and bringing the position to 46 shares worth $70. The position accounts for ﹤0.01% of the portfolio, ranked #5824.

Farther Finance Advisors first reported a position in ACTU in Q1 2026 and has held it in 2 quarters since. 12 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Farther Finance Advisors held 46 shares of Actuate Therapeutics worth $70 as of Q2 2026.
  • Farther Finance Advisors bought 39 Actuate Therapeutics shares in Q2 2026, an estimated $90.
  • Actuate Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5824 holding.
  • Farther Finance Advisors first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 12 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.